Prinomastat hydrochloride
Modify Date: 2024-01-10 19:03:10
Prinomastat hydrochloride structure
|
Common Name | Prinomastat hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 1435779-45-5 | Molecular Weight | 459.97 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C18H22ClN3O5S2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Prinomastat hydrochloridePrinomastat hydrochloride (AG3340 hydrochloride) is a broad spectrum, potent, orally active metalloproteinase (MMP) inhibitor with IC50s of 79, 6.3 and 5.0 nM for MMP-1, MMP-3 and MMP-9, respectively. Prinomastat hydrochloride inhibits MMP-2, MMP-3 and MMP-9 with Kis of 0.05 nM, 0.3 nM and 0.26 nM, respectively. Prinomastat hydrochloride can cross blood-brain barrier. Antitumor avtivity[1][2][3][4]. |
| Name | Prinomastat hydrochloride |
|---|
| Description | Prinomastat hydrochloride (AG3340 hydrochloride) is a broad spectrum, potent, orally active metalloproteinase (MMP) inhibitor with IC50s of 79, 6.3 and 5.0 nM for MMP-1, MMP-3 and MMP-9, respectively. Prinomastat hydrochloride inhibits MMP-2, MMP-3 and MMP-9 with Kis of 0.05 nM, 0.3 nM and 0.26 nM, respectively. Prinomastat hydrochloride can cross blood-brain barrier. Antitumor avtivity[1][2][3][4]. |
|---|---|
| Related Catalog | |
| Target |
MMP-9:5 nM (IC50) MMP-9:0.26 nM (Ki) MMP-2:0.05 nM (Ki) MMP-1:79 nM (IC50) MMP-13:6.3 nM (IC50) MMP-13:0.3 nM (Ki) |
| In Vitro | Prinomastat (AG3340; 0.1-1 µg/mL; 4 days; C57MG/Wnt1 cells) inhibits Wnt1-induced MMP-3 production. Reversal of Wnt1-induced EMT and β-catenin transcriptional activity by Prinomastat[1]. Co-culture of L/Wnt3a cells and CT7 cells increases the Topflash activity in CT7 cells, and co-culturing both L/Wnt3a cells and MMP-3 overexpressing C57MG cells with CT7 cells increases the Topflash luciferase activity in CT7 cells beyond the level observed with L/Wnt3a cells, and these effects are all suppressed by Prinomastat (AG3340)[1]. Inhibition of entry of C57MG/Wnt1 cells into S phase by Prinomastat corresponds to a decrease in expression of cyclin D1 and Erk1/2 phosphorylation. The effect of Prinomastat on Wnt1-induced migration is then examined using an in vitro wound assay. As anticipated, the migration of C57MG/Wnt1 cells is increased by 1.8-fold when compared with C57MG cells.The effect of Wnt1 on the cellular distribution of vimentin is reversed by Prinomastat in C57MG/Wnt1 cells[1]. Western Blot Analysis[1] Cell Line: C57MG/Wnt1 cells Concentration: 0.1 µg/mL, 1 µg/mL Incubation Time: 4 days Result: A significant decrease in MMP-3 promoter activity in C57MG/Wnt1 cells. |
| In Vivo | In a human fibrosarcoma mouse model (HT1080), the mice are treated therapeutically for 14-16 days with 50 mg/kg/day ip daily starting day 3 to 6 after tumour inoculation. Prinomastat is well tolerated by the animals, and there are no signs of weight loss or other adverse effects. Prinomastat has good tumour growth inhibition, with a short T1/2 of 1.6 hours[1]. |
| References |
| Molecular Formula | C18H22ClN3O5S2 |
|---|---|
| Molecular Weight | 459.97 |